1. Bruneau J, Ahamad K, Goyer M-È, et al. Management of opioid use disorders: a national
clinical practice guideline. CMAJ 2018; 190: E247-57. 2. McClain DA, Hug CC Jr …

Abstract Introduction and Aims Buprenorphine/naloxone is an evidence‐based treatment for
opioid use disorder, but an identified limitation is the period of required opioid abstinence …

Background and Objectives Buprenorphine's high‐binding affinity as a partial µ‐opioid
agonist displaces preexisting full agonists causing precipitated withdrawal, which requires …

Background The requirement for moderate withdrawal prior to initiation can be a barrier to
buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing …

Background and Objectives Buprenorphine/naloxone has been shown to be effective in the
treatment of opioid use disorder. Due to its pharmacological properties, induction can be …

Abstract Background Buprenorphine/naloxone (Suboxone) is a current first-line treatment for
opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone …

Background Buprenorphine is a partial µ-opioid receptor agonist used for maintenance
treatment of opioid dependence. Because of the partial agonism and high receptor affinity, it …

Low dose buprenorphine initiation, is an alternative method of initiating buprenorphine in
which the starting dose is very low and gradually increased to therapeutic levels over a …

Background and Objectives Buprenorphine extended‐release (BUP‐XR) is a monthly
injectable form of opioid agonist therapy. Before its administration, a minimum 7‐day …

Physician adoption of buprenorphine treatment of opioid dependence may be limited in part
by concerns regarding the induction process. Although national guidelines recommend …